Shionoya, K.; Sofuni, A.; Mukai, S.; Yamauchi, Y.; Tsuchiya, T.; Tanaka, R.; Tonozuka, R.; Yamamoto, K.; Nagai, K.; Matsunami, Y.;
et al. Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center. Cancers 2025, 17, 314.
https://doi.org/10.3390/cancers17020314
AMA Style
Shionoya K, Sofuni A, Mukai S, Yamauchi Y, Tsuchiya T, Tanaka R, Tonozuka R, Yamamoto K, Nagai K, Matsunami Y,
et al. Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center. Cancers. 2025; 17(2):314.
https://doi.org/10.3390/cancers17020314
Chicago/Turabian Style
Shionoya, Kento, Atsushi Sofuni, Shuntaro Mukai, Yoshiya Yamauchi, Takayoshi Tsuchiya, Reina Tanaka, Ryosuke Tonozuka, Kenjiro Yamamoto, Kazumasa Nagai, Yukitoshi Matsunami,
and et al. 2025. "Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center" Cancers 17, no. 2: 314.
https://doi.org/10.3390/cancers17020314
APA Style
Shionoya, K., Sofuni, A., Mukai, S., Yamauchi, Y., Tsuchiya, T., Tanaka, R., Tonozuka, R., Yamamoto, K., Nagai, K., Matsunami, Y., Kojima, H., Minami, H., Hirakawa, N., Zhan, Q., & Itoi, T.
(2025). Initial Use Experience of Durvalumab Plus Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in a Japanese Territory Center. Cancers, 17(2), 314.
https://doi.org/10.3390/cancers17020314
